Claims for Patent: 9,388,159

Summary for Patent: 9,388,159

Title:	Substituted diazaspiroalkanes as androgen receptor modulators
Abstract:	This invention provides for compounds of the Formula II: ##STR00001## wherein A, B, Het, R.sub.1, R.sub.2 and R.sub.3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
Inventor(s):	Jung; Michael E. (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (New York, NY)
Assignee:	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:	14/318,234
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,388,159
Patent Claims:	1. A compound having the Formula II: ##STR00026## wherein Het is a heterocyclic unit of 6 atoms comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, or sulfur; 0 or 1 double-bonded substituent on the heterocyclic unit selected from the group consisting of oxygen and sulfur; and 3 to 4 single-bonded substituents on the heterocyclic unit independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, arylalkenyl, arylalkynyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogen, CN, NO.sub.2, OR.sub.11, SR.sub.11, NR.sub.11R.sub.12, NH(CO)OR.sub.11, NH(CO)NR.sub.11R.sub.12, NR.sub.12(CO)R.sub.11, O(CO)R.sub.11, O(CO)OR.sub.11, O(CS)R.sub.11, NR.sub.12(CS)R.sub.11, NH(CS)NR.sub.11R.sub.12, NR.sub.12(CS)OR.sub.11, wherein two of said single-bonded substituents may be connected together with the atoms to which they are bonded to form a cycle, which is aryl, substituted aryl, heterocyclic aromatic or non-aromatic, substituted heterocyclic aromatic or non-aromatic, cycloalkyl, or substituted cycloalkyl; A is sulfur and B is oxygen; R.sub.11 and R.sub.12 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, aryl, substituted aryl, arylalkyl, arylalkenyl, arylalkynyl, heterocyclic aromatic or non-aromatic, or substituted heterocyclic aromatic or non-aromatic, wherein R.sub.11 and R.sub.12, both on the same single bonded substituent, can be connected together with the atoms to which they are bonded to form a cycle, which can be heterocyclic aromatic or non-aromatic, or substituted heterocyclic aromatic; R.sub.1 is selected from aryl and substituted aryl; R.sub.2 and R.sub.3 together with the carbon to which they are linked, form a cycloalkyl or substituted cycloalkyl; wherein each substituted alkyl is substituted with one or more groups selected from hydroxy, bromo, fluoro, chloro, iodo, mercapto, cyano, alkylthio, heterocyclyl, aryl, heteroaryl, carboxy, carbalkoyl, alkyl, alkenyl, nitro, amino, alkoxy, or amido; wherein each substituted cycloalkyl, substituted alkenyl, substituted alkynyl, or substituted heterocyclic non-aromatic is substituted with one or more groups selected from halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, alkylthio, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, heteroaryl, carboxy, carbalkoyl, alkenyl, or amido; wherein each substituted arylalkyl, arylalkenyl, or arylalkynyl is substituted on the aryl portion with one or more groups selected from halogen, alkyl, alkoxy, hydroxyl, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, alkylthio, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, heteroaryl, carboxyl, carbalkoyl, alkenyl, or amido; wherein each substituted aryl or substituted aromatic is substituted with one or more groups selected from halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, carbamoyl, alkylcarbamoyl, amidified carboxy, amidified carboxyalkyl, alkyl amidified carboxyalkyl, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino, arylsulfonaminocarbonyl, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, carboxy, carbalkoyl, alkoxy, amido, amino, or amino substituted with one or two substituents selected from the group consisting of alkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylcarbonyl, arylalkenyl, arylalkynyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, heteroarylthio, arylthioalkyl, alkoxyarylthio, arylaminocarbonyl, arylcarbonyloxy, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino, and arylsulfonaminocarbonyl; and wherein substituted heteroaryl or substituted heterocyclic aromatic is substituted with one, two, three or four groups selected from halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, alkylthio, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, heteroaryl, carboxy, carbalkoyl, alkenyl, or amido. 2. The compound of claim 1, wherein R.sub.1 is selected from the group consisting of phenyl and substituted phenyl. 3. The compound of claim 2, wherein phenyl is substituted with fluoro. 4. The compound of claim 2, wherein phenyl is substituted with methyl. 5. The compound of claim 2, wherein phenyl is substituted with --C(O)NHCH.sub.3. 6. The compound of claim 1, wherein Het is selected from the group consisting of ##STR00027## wherein R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, aryl alkenyl, arylalkynyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogen, CN, NO.sub.2, OR.sub.11, SR.sub.11, NR.sub.11R.sub.12, NH(CO)OR.sub.11, NH(CO)NR.sub.11R.sub.12, NR.sub.12(CO)R.sub.11, O(CO)R.sub.11, O(CO)OR.sub.11, O(CS)R.sub.11, NR.sub.12(CS)R.sub.11, NH(CS)NR.sub.11R.sub.12, NR.sub.12(CS)OR.sub.11; or any of R.sub.4, R.sub.5, R.sub.6, and R.sub.7 can be connected to any of R.sub.4, R.sub.5, R.sub.6, and R.sub.7 to form a cycle which is aryl, substituted aryl, heterocyclic aromatic or non-aromatic, substituted heterocyclic aromatic or non-aromatic, cycloalkyl, or substituted cycloalkyl. 7. The compound of claim 6, wherein Het is selected from the group consisting of ##STR00028## 8. The compound of claim 6, wherein R.sub.4 is selected from the group consisting of CN and NO.sub.2; R.sub.5 is selected from the group consisting of halogenated alkyl, halogenated alkenyl, halogenated alkynyl, and halogen; and R.sub.6, and R.sub.7 are independently selected from the group consisting of hydrogen, alkyl, and halogen. 9. The compound of claim 6, wherein Het is selected from the group consisting of ##STR00029## 10. The compound of claim 1, wherein R.sup.2 and R.sup.3, together with the carbon to which they are linked, form a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 11. The compound of claim 1, wherein R.sub.2 and R.sub.3, together with the carbon to which they are linked, form a cycloalkyl. 12. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant. 13. The pharmaceutical composition of claim 12, formulated to deliver a therapeutically effective amount of the compound when administered (i) in a single dosage form; (ii) in a divided dosage form for delivery multiple times over the span of one day; (iii) continually; or (iv) continuously. 14. The pharmaceutical composition of claim 13, wherein the compound is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 15. The pharmaceutical composition of claim 13, wherein the compound is 5-(8-oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]oct-7-yl)-3-trifl- uoromethylpyridine-2-carbonitrile. 16. The pharmaceutical composition of claim 12, comprising a therapeutically effective amount of the compound formulated in an oral dosage form. 17. The pharmaceutical composition of claim 16, wherein the compound is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 18. The pharmaceutical composition of claim 16, wherein the compound is 5-(8-oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]oct-7-yl)-3-trifl- uoromethylpyridine-2-carbonitrile. 19. The pharmaceutical composition of claim 12, formulated in a divided dosage form suitable for delivering a therapeutically effective amount of the compound when administered to a human patient multiple times over the span of one day. 20. The pharmaceutical composition of claim 19, wherein the compound is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 21. The pharmaceutical composition of claim 19, wherein the compound is 5-(8-oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]oct-7-yl)-3-trifl- uoromethylpyridine-2-carbonitrile. 22. The pharmaceutical composition of claim 12, formulated in an oral dosage form and containing from 1 mg to 1000 mg of the compound. 23. The pharmaceutical composition of claim 22, wherein the compound is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 24. The pharmaceutical composition of claim 22, wherein the compound is 5-(8-oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]oct-7-yl)-3-trifl- uoromethylpyridine-2-carbonitrile. 25. The pharmaceutical composition of claim 12, formulated in an oral dosage form and containing from 1 mg to 500 mg of the compound. 26. The pharmaceutical composition of claim 25, wherein the compound is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 27. The pharmaceutical composition of claim 25, wherein the compound is 5-(8-oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]oct-7-yl)-3-trifl- uoromethylpyridine-2-carbonitrile. 28. The pharmaceutical composition of claim 12, comprising a therapeutically effective amount of said compound. 29. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition has a form selected from a solution, dispersion, suspension, powder, capsule, tablet, and pill. 30. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition has a form selected from a time release capsule, time release tablet, and time release pill. 31. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is a capsule. 32. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is a tablet. 33. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is a pill.